Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott prepares to launch ovarian cancer test

This article was originally published in The Gray Sheet

Executive Summary

Abbott plans a U.S. rollout of its Architect HE4 assay, the first automated diagnostic for monitoring the recurrence or progression of epithelial ovarian cancer, by the end of 2010, pending FDA approval of a December 2009 510(k) submission, firm says Feb. 8. The test, a two-step immunoassay for detection of HE4 antigen in human serum, uses chemilumuniscent technology to measure relative light units of the reaction to HE4 - shown in a 2003 study by Hellstrom, et al., to be the best biomarker for Stage 1 ovarian cancer. The test received European CE mark approval in January
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel